Compare Ares Capital Corporation (ARCC) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ares Capital Corporation vs Crispr Therapeutics AG — how do they compare? Ares Capital Corporation trades at $19.97 (market cap $14.34B), while Crispr Therapeutics AG trades at $54.08 (market cap $5.23B). The key difference: Ares Capital Corporation is far larger — about 2.7× Crispr Therapeutics AG's market cap, and Ares Capital Corporation pays a 9.61% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| ARCC | CRSP | |
|---|---|---|
Market Cap | $14.34B | $5.23B |
Sector | Financials | Health |
52-Week High | $22.68 | $76.78 |
52-Week Low | $17.45 | $44.34 |
Dividend Yield | 9.61% | — |
Enterprise Value | — | $3.65B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
